Here are five quick facts:
1. Oppenheimer set a $28 price target for Globus Medical shares.
2. Globus Medical currently has a “buy” rating.
3. There is a potential upside of 12.22 percent.
4. Globus Medical traded up 0.6 percent yesterday mid-day.
5. Market cap for the company is $2.36 million with a P/E ratio of 25.72.
Recently, WallachBeth Capital raised the price target on Globus to $30 from $26 and also gave the company a “buy” rating earlier this month. Leerink Swann also raised target price to $29 and gave the company an “outperform” rating, according to the report.
More articles on orthopedic devices:
Greatbatch short interest drops by 8.5% — 4 things to know
Amedica to present CASCADE clinical results
Spine device stock report: 5 key companies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
